DOCSLIB.ORG

Gerven J. V. HH 2010 01.Pdf(1.4

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gerven J. V. HH 2010 01.Pdf(1.4 Biomarker: Clinical Validation for Intended Use Joop van Gerven professor of clinical neuropsychopharmacology Centre for Human Drug Research Leiden The Netherlands to the memory of Hermann Fuder Lecture Contents What are biomarkers? question-based drug development What can you do with them? examples from GABA-ergic research Biomarker Definitions A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. (NIH Biomarkers Definitions Working Group, 2001) A quantitative measure that is on the causal path between drug administration and effect. (EU COST-B Biomarker Working Party, Danhof, 2005) type 0 type 1 type 2 type 3 type 4 type 5 type 6 phenotype drug target target physiological patho- clinical genotype concentration occupancy activation response physiological response response …the causal path… A Practical Biomarker Definition: Tools to Answer Questions in Drug Development population action site drug development is case building pharmacology clinical window Question-Based Drug Development: main issues for early development 1. Does the drug reach its target? 2. Does the drug have pharmacological activity/-ies? 3. Does the drug affect intended (patho)physiological processes? 4. What is the window between desired and undesirable effects? Example 1 First-in-human study Fast- and short-acting benzodiazepines New sedative in anesthesia Two new compounds vs midazolam Question-Based Development: Action Site 1: does the drug reach its target? Question-Based Development: Action Site 1: does the drug reach its target? Membrane Receptors/Ion Channels GABA-A-receptors glutamate NMDA channel L-type Ca2+ channel Membrane Transporters 5HT-transporter *18F-flumazenil dopamine-transporter p-Glycoprotein * Vesicular Transporters vesicular Monoamine Transporter-2 vesicular Acetylcholine Transporter Neurotransmitter Precursors F-DOPA Enzymes MAO-A, MAO-B acetylcholinesterase Question-Based Development: Action Site 1: does the drug reach its action site? single rising dose study of two novel benzodiazepines vs positive control •1 mg •2 mg •3 mg •500 •midazolam •500 •450 •400 •400 •350 •SPV (deg/sec) •SPV •300 •SPV (deg/sec) •300 •200 •250 •0 •60 •120 •180 •240 •300 •0 •50 •100 •150 •Time (min) •effect compartment concentration (µg/L) Ro 8684: shorter duration of Ro 6791: more potent than midazolam, action than midazolam equipotent at 3 mg (+20 µg/L) Dingemanse J, Van Gerven JMA, Schoemaker HC et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzo¬diazepine, in comparison to mida¬zolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997;44:477 -486 Van Gerven JMA, Roncari G, Schoemaker HC et al. Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzo¬diazepine, in comparison to midazolam during first administration to healthy male subjects. Br J Clin Pharmacol 1997;44:487-493 Question-Based Development: Pharmacology 2: does the drug have a pharmacological effect? [C] E PK/PD Question-Based Development: Pharmacology 2: does the drug have a pharmacological effect? GABAA R concentration-related effects are pharmacological biomarkers! Question-Based Development: Pharmacology 2: how relevant are the pharmacological effects? A. Can biomarkers show competitive (dis)advantage? B. Can biomarkers predict adverse effects? C. Can biomarkers predict therapeutic doses? effect profiling positive controls NeuroCart: multimodal CNS-profiling in early drug development • Saccadic and smooth pursuit eye movement • Memory testing • Adaptive tracking • Finger tapping • Body sway • Visual analogue scales • Psychometric questionnaires NeuroCart • Electroencephalography • Polysomnography • Other CNS function tests • Symbol Digit Substitution Test • Critical Flicker Fusion • Stroop Conflict Task • Neuroendocrine measures • Autonomic function tests Data-Intensive Phase 1 ScreenCNS -180 -120 -75 -60 -45 0h 30 60 75 90 105 120 135 150 180 195 210 240 255 270 6h 8h 12h 21h FU practice Assessment Informed Consent X Demography X Incl./Exclusion X Medical history X Physical examination X Body Weight X Virology X Thyroid function test X Routine Lab +Urinalysis X X X Urine drug screen X X Concomitant Medications X X X Breath alcohol test X Meals/snack X XXXX Drug administration X Verbal learning X Delayed recall X Cognitive testing X 2X X X XXX X Adaptive trackingX XXXXXXXXXXXXX PK/PD Saccadic eye movements X XXXXXXXXXXXXX Smooth pursuit X XXXXXXXXXXXXX Body sway X XXXXXXXXXXXXX VAS (Bond & Lader) X XXXXXXXXXXXXX VAS (Bowdle) X XXXXXXXXXXXXX EEG X X XX X X XX XX XXX NeuroCart PK blood sampling X XXXX X X X X X XX X X Auricular temperature X X X XXX XXX Respiratory rate X X X Orthostatic BP/Pulse X X Supine BP /Pulse X X X XXX XXX Resting 12-Lead ECG X X X AE follow up X X X X XXX XXX Discharge from unit X Multimodal Pharmacological Effect Profiling: PK/PD-analyses show drug-specific pharmacological effect profiles VAS alertness SPV adaptive tracking body sway 3.2 40 660 5 3.0 20 600 ) 0 % e ( 2.8 0 540 manc -5 or f r e 2.6 ng P -20 i k 480 -10 (mm) Sway Log Body ac GABA-agonists r Delta VAS Alertness (mm) a T t 2.4 Saccadic Peak Velocity (deg/sec) Velocity Peak Saccadic -40 420 Del -15 -60 2.2 360 -20 -120 0 120 240 360 480 600 720 840 -120 0 120 240 360 480 600 720 840 -120 0 120 240 360 480 600 720 840 -120 0 120 240 360 480 600 720 840 Time (min) Time (min) Time (min) Time (min) 600 70 3.2 6 550 3.0 60 0 ) 2.8 500 mm) ( ay w ance (% -6 50 S 2.6 ody 450 rform e B -12 G 2.4 VAS Alertness (mm) VAS Alertness ng P LO Saccadic Peak Velocity (deg/sec) Velocity Peak Saccadic 40 acki M-antagonists r 400 T -18 2.2 30 2.0 350 -24 -60 0 60 120 180 240 300 360 420 480 540 600 -60 0 60 120 180 240 300 360 420 480 540 600 -60 0 60 120 180 240 300 360 420 480 540 600 -120 0 120 240 360 480 600 720 840 Time (min) Time (min) Time (min) Time (min) 590 3.2 580 4 570 560 3.0 80 3 550 540 530 2 2.8 520 CB1-agonists 60 510 1 500 2.6 490 0 480 2.4 470 -1 (mm) Sway LOG Body 40 460 VAS Alertness (mm) VAS Alertness Saccadic peak velocity (deg/sec) velocity peak Saccadic 450 -2 440 2.2 430 -3 420 2.0 20 410 (%)(change) performance Tracking average -4 -60 0 60 120 180 240 300 360 420 480 540 600 -120 0 120 240 360 480 600 0246810 0 120 240 360 480 600 Time (min) Time (min) Time (min) … Time (h) Multimodal Pharmacological Effect Profiling: effect profiles are drug-class-specific VAS ALERTNESS VAS EXTERNAL VAS INTERNAL SACCADIC PEAK VELOCITY SMOOTH PURSUITADAPTIVE TRACKINGBODY SWAY SLEEP During night Sleep deprivation 1 night L-830409 0.25 mg PO L-830409 0.75 mg PO L-830982 0.5mg PO L-830982 1.5mg PO PARTIAL L-83982 2mg PO GABAA Bretazenil 0.5mg SL Diazepam 10mg PO Lorazepam 2 mg PO Lorazepam 2 mg PO Lorazepam 2mg PO Midazolam 0.1mg/kg IV Midazolam 0.1mg/kg IV GABAA Midazolam 0.1mg/kg IV Nitrazepam 5mg PO Nitrazepam 5mg PO (Jap) RO486791 10mg IV RO488684 10mg IV SL651498 2.5mg PO SL651498 25mg PO Temazepam IV Temazepam 20mg PO Temazepam IV Fast Zolpidem 10mg PO Breta 0.5mg SL+Ethanol 5.0% IV Diaz 10mg PO+Ethanol 0.6g/L TC Ethanol 0.6g/L TCI ETHANOL Ethanol 0.6g/L TCI Ethanol 0.6g/L TCI THC 2+4+6+6mg IH THC 2+4+6+8mg IH THC ORG 28611#6 IV ORG26828 #5 ug/kg IV AVE16255HTP 120 100mg mg PO 5HTP 100mg PO + Carbidopa 5HTP 100mg PO + Carbidopa 5HTP 200 mg PO + Carbidopa 5HTP 200mg PO 5HTP 200mg PO+Carb+Dom 10 mg 5HTP 200mg PO+Carb+Gran 2mg 5HTP 200mg PO+Carbidopa 5HTP 5HTP 300 mg PO + Carbidopa 5HT Dexfenfluramine 0.5mg/kg PO Amitriptyline 50mg PO 5HT ANT Rizatriptan 10mg PO Sumatriptan 50mg PO mCPP 0.1mg/kg IV mCPP 0.5mg/kg PO SB742457 50mg PO SB742457 50mg PO + Risper 2mg Risperidone 2mg PO DOPAMINE ANT Sulpiride 400 mg PO DOPAMINE Haloperidol 3mg PO Lisuride 0.2 mg PO GPI1 100 mg PO GPI1 300 mg PO GPI1 750 mg PO Scopolamine 0.5mg IV Scopolamine 0.5mg IV OTHER MK0869 160mg PO MK0869 160mg PO+Amitriptyline Talnetant 200mg PO Org25935 0.5mg PO R213129 30mg ACT-078573 1000mg PO ACT-078573 400mg PO O SPO2 80% 2 SPO2 90% 0 6 2 6 20 20 40 . 0 0 0 0 0 0 0 0 0 0 0 5 -60 -40 - -0.4 -0.2 0.0 0.2 0.4 0 0.8-0.4 -0.2 0.0 0. 0.4 0 50 00 -5 5-30 -20 -1 1 -30 -20 -1 10 . .5 . -1 -1 -0.5 0 0.5 1 1 2 2 EOD (5-95% CI) EOD (5-95% CI) EOD (5-95% CI) EOD (5-95% CI) EOD (5-95% CI) EOD (5-95% CI) EOD (5-95% CI) Example 2 First-in-human study New hypnotic Orexin antagonist vs zolpidem Question-Based Development: Pharmacology benchmarking biomarkers vs positive controls a) Adapative tracking performance b) Saccadic peak velocity 10 40 20 5 0 first-in-man of orexin -20 0 -40 Placebo -60 Placebo -5 Zolpidem Zolpidem antagonist 1000 mg -80 1000 mg 400 mg 400 mg -100 Mean change from baseline (%) change from baseline Mean -10 200 mg 200 mg 100 mg (degree/s) baseline from change Mean 100 mg -120 -15 -140 0 2 4 6 8 10 12 0 2 4 6 8 10 12 single-ascending dose Time after administration (h) Time after administration (h) NeuroCart battery c) Body sway d) Smooth pursuit 720 20 zolpidem as positive 600 Placebo Zolpidem 480 1000 mg 10 400 mg 360 200 mg control 100 mg 240 0 120 0 Placebo Zolpidem -10 -120 1000 mg Mean change from baseline (%) change baseline from Mean Mean change from baseline (mm) baseline from change Mean 400 mg -240 200 mg 100 mg -360 -20 0 2 4 6 8 10 12 almorexant 200-400 mg 0 2 4 6 8 10 12 Time after administration (h) Time after administration (h) similar to zolpidem 10 mg somewhat less postural e) Delta Pz −Oz f) Theta Pz −Oz 1.5 1.5 Placebo Placebo Zolpidem Zolpidem 1000 mg 1000 mg instability
Load more

Recommended publications
  • Insomnia and Anxiety in Older People Sleeping Pills Are Usually Not the Best Solution
    ® Insomnia and anxiety in older people Sleeping pills are usually not the best solution lmost one-third of older people in the people who take one of United States take sleeping pills. These these medicines sleep medicines are also sometimes called only a little longer and A“sedative-hypnotics” or “tranquilizers.” They better than those who affect the brain and spinal cord. don’t take a medicine. Doctors prescribe some of these medicines Sleeping pills can for sleep problems. Some of these medicines have serious side effects. also can be used to treat other conditions, such All sedative-hypnotic medicines have special as anxiety or alcohol withdrawal. Sometimes, risks for older adults. Seniors are likely to be doctors also prescribe certain anti-depressants more sensitive to the medicines’ effects than for sleep, even though that’s not what they’re younger adults. And these medicines may designed to treat. stay in older people’s bodies longer. These Most older adults should first try to treat their medicines can cause confusion and memory insomnia without medicines. According to the problems that: American Geriatrics Society, there are safer and • Increase the risk of falls and hip fractures. better ways to improve sleep or reduce anxiety. These are common causes of hospital stays Here’s why: and death in older people. Sleeping pills may not help much. • Increase the risk of car accidents. Many ads say that sleeping pills help people get a full, restful night’s sleep. But studies show that this is not exactly true in real life. On average, The new “Z” medicines also have risks.
    [Show full text]
  • Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam
    Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam Tjiauw-Ling Tan, MD, Edward 0. Bixler, PhD, Anthony Kales, MD, Roger J. Cadieux, MD, and Amy L. Goodman, MD Hershey, Pennsylvania A psychiatric syndrome characterized by agita­ Sleep Disorders Clinic. He began taking triazolam tion, paranoid ideation, depersonalization, and de­ at bedtime in a 0.5-mg dose eight months before pression, as well as paresthesias and hyperacusis, his referral. Although the drug was effective ini­ has been attributed to administration of triazolam tially, tolerance developed, causing the patient to (Halcion).1 The occurrence of these reactions led gradually increase the dosage until eventually he to the removal of the drug from the market in the was taking a total of 1.5 mg nightly. Netherlands. Isolated behavioral side effects that The physical examination revealed no contribu­ include amnesia2-4 and hallucinations5 have also tory conditions. However, assessment of the pa­ been reported with administration of triazolam. tient’s mental status revealed that he was extreme­ Rebound insomnia6 and early morning insom­ ly guarded and suspicious and preoccupied with nia,7 both associated with increases in daytime his sleeplessness to the degree that this hypochon­ anxiety,7,8 are withdrawal syndromes known driacal concern had a delusional quality. He also to occur with rapidly eliminated benzodiazepine described two episodes indicating memory impair­ hypnotics such as triazolam. Rebound insomnia ment; both incidents occurred in the late afternoon consists of a marked increase in wakefulness and involved preparing to eat certain foods, which above baseline levels following drug withdrawal.
    [Show full text]
  • Comparison of Short-And Long-Acting Benzodiazepine-Receptor Agonists
    J Pharmacol Sci 107, 277 – 284 (2008)3 Journal of Pharmacological Sciences ©2008 The Japanese Pharmacological Society Full Paper Comparison of Short- and Long-Acting Benzodiazepine-Receptor Agonists With Different Receptor Selectivity on Motor Coordination and Muscle Relaxation Following Thiopental-Induced Anesthesia in Mice Mamoru Tanaka1, Katsuya Suemaru1,2,*, Shinichi Watanabe1, Ranji Cui2, Bingjin Li2, and Hiroaki Araki1,2 1Division of Pharmacy, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan 2Department of Clinical Pharmacology and Pharmacy, Neuroscience, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan Received November 7, 2007; Accepted May 15, 2008 Abstract. In this study, we compared the effects of Type I benzodiazepine receptor–selective agonists (zolpidem, quazepam) and Type I/II non-selective agonists (zopiclone, triazolam, nitrazepam) with either an ultra-short action (zolpidem, zopiclone, triazolam) or long action (quazepam, nitrazepam) on motor coordination (rota-rod test) and muscle relaxation (traction test) following the recovery from thiopental-induced anesthesia (20 mg/kg) in ddY mice. Zolpidem (3 mg/kg), zopiclone (6 mg/kg), and triazolam (0.3 mg/kg) similarly caused an approximately 2-fold prolongation of the thiopental-induced anesthesia. Nitrazepam (1 mg/kg) and quazepam (3 mg/kg) showed a 6- or 10-fold prolongation of the anesthesia, respectively. Zolpidem and zopiclone had no effect on the rota-rod and traction test. Moreover, zolpidem did not affect motor coordination and caused no muscle relaxation following the recovery from the thiopental-induced anesthesia. However, zopiclone significantly impaired the motor coordination at the beginning of the recovery. Triazolam significantly impaired the motor coordination and muscle relaxant activity by itself, and these impairments were markedly exacerbated after the recovery from anesthesia.
    [Show full text]
  • The Renaissance in Psychedelic Research: What Do Preclinical Models Have 2 to Offer
    CHAPTER The renaissance in psychedelic research: What do preclinical models have 2 to offer Kevin S. Murnane1 Department of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center, Atlanta, GA, United States 1Corresponding author: Tel.: +1-678-547-6290; Fax: +1-678-547-6423, e-mail address: [email protected] Abstract Human research with psychedelics is making groundbreaking discoveries. Psychedelics mod- ify enduring elements of personality and seemingly reduce anxiety, depression, and substance dependence in small but well-designed clinical studies. Psychedelics are advancing through pharmaceutical regulatory systems, and neuroimaging studies have related their extraordinary effects to select brain networks. This field is making significant basic science and translational discoveries, yet preclinical studies have lagged this renaissance in human psychedelic research. Preclinical studies have a lot to offer psychedelic research as they afford tight control of experimental parameters, subjects with documented drug histories, and the capacity to elucidate relevant signaling cascades as well as conduct invasive mechanistic studies of neurochemistry and neural circuits. Safety pharmacology, novel biomarkers, and pharmaco- kinetics can be assessed in disease state models to advance psychedelics toward clinical practice. This chapter documents the current status of psychedelic research, with the thematic argument that new preclinical studies would benefit this field. Keywords Psychedelic, Preclinical, Serotonin, Neuroimaging, Alcoholism, Anxiety, Depression, Substance dependence 1 INTRODUCTION The term psychedelic has come to be associated with a broad class of drugs with diverse chemical, pharmacological, and psychoactive effects. Alternative nomencla- tures have used hallucinogen, entheogen, psychotomimetic and other appellations to Progress in Brain Research, Volume 242, ISSN 0079-6123, https://doi.org/10.1016/bs.pbr.2018.08.003 25 © 2018 Elsevier B.V.
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Comparative Cue Generalisation Profiles of L-838,417, SL651498
    JPET Fast Forward. Published on December 8, 2005 as DOI: 10.1124/jpet.105.094003 JPET FastThis Forward.article has not Published been copyedited on and December formatted. The 8, final 2005 version as DOI:10.1124/jpet.105.094003may differ from this version. JPET #94003 Title Page Comparative cue generalisation profiles of L-838,417, SL651498, zolpidem, CL218,872, ocinaplon, bretazenil, zopiclone and various benzodiazepines in chlordiazepoxide and zolpidem drug Downloaded from discrimination jpet.aspetjournals.org Mirza NR, Rodgers RJ and Mathiasen LS NeuroSearch A/S, 93 Pederstrupvej, Ballerup, DK-2750, Denmark (NRM, LSM); Behavioural Neuroscience Laboratory, Institute of Psychological at ASPET Journals on October 1, 2021 Sciences, University of Leeds, Leeds LS2 9JT, England (JRR, LSM) 1 Copyright 2005 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on December 8, 2005 as DOI: 10.1124/jpet.105.094003 This article has not been copyedited and formatted. The final version may differ from this version. JPET #94003 Running Title Page: Subtype-selective GABAA receptor modulators in drug discrimination Contact and address for correspondence: Naheed R. Mirza Department of In-vivo Pharmacology NeuroSearch A/S 93 Pederstrupvej Downloaded from DK-2750 Ballerup Denmark Tele: +45 44 60 82 71 jpet.aspetjournals.org FAX: +45 44 60 80 80 E-mail: [email protected] at ASPET Journals on October 1, 2021 Number of text pages: 19 Number of tables: 0 Number of figures: 4 Number of references: 35 Number of words in Abstract: 252 Number of words in Introduction: 1028 Number of words in Discussion: 1598 Non-standard abbreviations: None Preferred section assignment: Behavioural Pharmacology 2 JPET Fast Forward.
    [Show full text]
  • Human Pharmacology of Positive GABA-A Subtype-Selective Receptor Modulators for the Treatment of Anxiety
    www.nature.com/aps REVIEW ARTICLE Human pharmacology of positive GABA-A subtype-selective receptor modulators for the treatment of anxiety Xia Chen1,2,3,4, Joop van Gerven4,5, Adam Cohen4 and Gabriel Jacobs4 Anxiety disorders arise from disruptions among the highly interconnected circuits that normally serve to process the streams of potentially threatening stimuli. The resulting imbalance among these circuits can cause a fundamental misinterpretation of neural sensory information as threatening and can lead to the inappropriate emotional and behavioral responses observed in anxiety disorders. There is considerable preclinical evidence that the GABAergic system, in general, and its α2- and/or α5-subunit- containing GABA(A) receptor subtypes, in particular, are involved in the pathophysiology of anxiety disorders. However, the clinical efficacy of GABA-A α2-selective agonists for the treatment of anxiety disorders has not been unequivocally demonstrated. In this review, we present several human pharmacological studies that have been performed with the aim of identifying the pharmacologically active doses/exposure levels of several GABA-A subtype-selective novel compounds with potential anxiolytic effects. The pharmacological selectivity of novel α2-subtype-selective GABA(A) receptor partial agonists has been demonstrated by their distinct effect profiles on the neurophysiological and neuropsychological measurements that reflect the functions of multiple CNS domains compared with those of benzodiazepines, which are nonselective, full GABA(A) agonists. Normalizing the undesired pharmacodynamic side effects against the desired on-target effects on the saccadic peak velocity is a useful approach for presenting the pharmacological features of GABA(A)-ergic modulators. Moreover, combining the anxiogenic symptom provocation paradigm with validated neurophysiological and neuropsychological biomarkers may provide further construct validity for the clinical effects of novel anxiolytic agents.
    [Show full text]
  • Amygdala-Specific Reduction Ofα1-GABAA Receptors Disrupts the Anticonvulsant, Locomotor, and Sedative, but Not Anxiolytic, Effe
    The Journal of Neuroscience, May 26, 2010 • 30(21):7139–7151 • 7139 Behavioral/Systems/Cognitive ␣ Amygdala-Specific Reduction of 1-GABAA Receptors Disrupts the Anticonvulsant, Locomotor, and Sedative, But Not Anxiolytic, Effects of Benzodiazepines in Mice Scott A. Heldt2 and Kerry J. Ressler1,2 1Howard Hughes Medical Institute and 2Department of Psychiatry and Behavioral Sciences, Yerkes National Primate Research Center, Emory University, Atlanta, Georgia 30329 The heterogeneity and distribution of GABAA receptor subunits mediates differential roles in behavior. It is thought that particular behavioral responses to benzodiazepine (BZ) ligands might be associated with an action at a regionally defined receptor subtype. However, the role of specific GABAA receptor subtypes in particular brain regions is less clear. Such detailed knowledge of regional ␣ 1-GABAA receptor function will advance our understanding of the neural circuitry underlying the role of GABAA receptors and the ␣ effects of GABAA-modulating drugs on behavior. By combining inducible, site-specific 1 subunit deletion, using a lentivirus expressing Cre-recombinase in mice with the ␣1 subunit gene flanked by loxP sites, we examine baseline and pharmacological ␣ ␣ effects of deletion of amygdala 1-GABAA receptors. We find that amygdala-specific reduction of 1 receptor subunits does not affect mRNA or protein levels of amygdala ␣2or␣3 subunit receptors. Nor does this inducible reduction affect baseline locomo- tion or measures of anxiety. However, we also find that this inducible, site-specific deletion does disrupt the normal sedative- locomotor inhibition as well as the anticonvulsive effects, of two distinct BZ-site ligands, diazepam and zolpidem, which is relatively ␣1-subunit selective.
    [Show full text]
  • Each of These Protein Subunits Consists of Large Hydrophobic NH
    AN UPDATED UNIFIED PHARMACOPHORE MODEL OF THE BENZODIAZEPINE BINDING SITE ON γ-AMINOBUTYRIC ACIDA RECEPTORS: CORRELATION WITH COMPARATIVE MODELS T. Clayton1, J. L. Chen1, M. Ernst4, L. Richter4,5, B. A. Cromer2, C. J. Morton2, H. Ng2, C. Cook- Kaczorowski1, F. J. Helmstetter3, R. Furtmüller4, G. Ecker5, M. W. Parker2, W. Sieghart4 and J. M. Cook1* 1Departments of Chemistry & Biochemistry and 3Psychology, University of Wisconsin-Milwaukee, Milwaukee, WI 53201; 2St. Vincent’s Institute of Medical Research, Victoria 3065, Australia; 4Division of Biochemistry & Molecular Biology, Center for Brain Research, Medical University Vienna, A-1090, Vienna, Austria; 5Department of Medicinal Chemistry, University Vienna, A-1090 Vienna, Austria 1 ABSTRACT: A successful unified pharmacophore/receptor model which has guided the synthesis of subtype selective compounds is reviewed in the light of recent developments both in ligand synthesis and structural studies of the binding site itself. The evaluation of experimental data in combination with a comparative model of the α1β2γ2 GABAA receptor leads to an orientation of the pharmacophore model within the Bz BS. Results not only are important for the rational design of selective ligands, but also for the identification and evaluation of possible roles which specific residues may have within the benzodiazepine binding pocket. Key words: AMINOBUTYRIC ACID(A) RECEPTORS; GATED ION CHANNELS; GABA-A; COMPUTER-ASSISTED ANALYSIS; BENZODIAZEPINE 2 The GABAA receptor is the major inhibitory neurotransmitter receptor
    [Show full text]
  • Tolerance Liability of Diazepam Is Dependent on the Dose Used For
    Pharmacological Reports Copyright © 2012 2012, 64, 11161125 by Institute of Pharmacology ISSN 1734-1140 Polish Academy of Sciences Toleranceliabilityofdiazepamisdependent onthedoseusedforprotractedtreatment JovanaDivljakoviæ,MarijaMiliæ, TamaraTimiæ,MiroslavM.Saviæ DepartmentofPharmacology,FacultyofPharmacy,UniversityofBelgrade,VojvodeStepe450,11221Belgrade, Serbia Correspondence: MiroslavM.Saviæ, e-mail:[email protected] Abstract: Background: Behavioral effects of benzodiazepines following repeated exposure vary according to the intrinsic efficacy of the ben- zodiazepinestudied,treatmentscheduleandthebehavioralparametersevaluated. Methods: We applied the behavioral paradigms of spontaneous locomotor activity, elevated plus maze and grip strength to investi- gate the sedative, anxiolytic and myorelaxant effect of acute challenge with 2 mg/kg diazepam administered after 14 days of protracted treatment with 0.5, 2 or 10 mg/kg of diazepam. In addition, we studied the effects of everyday handling and intraperito- neal(ip)administrationonanimalbehavior. Results: Tolerance to the sedative effect of 2 mg/kg diazepam ensued after 14 days of protracted treatment with 2 and 10 mg/kg of diazepam. In contrast, treatment with the lowest dose (0.5 mg/kg) of diazepam resulted in potentiation of the sedative effect of acute challenge with 2 mg/kg diazepam thus confounding the detection of the anxiolytic effect of diazepam. A sensitization-like response to the anxiolytic action of 2 mg/kg diazepam was seen after protracted treatment with the
    [Show full text]
  • Drug-Facilitated Sexual Assault in the U.S
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Estimate of the Incidence of Drug-Facilitated Sexual Assault in the U.S. Document No.: 212000 Date Received: November 2005 Award Number: 2000-RB-CX-K003 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. AWARD NUMBER 2000-RB-CX-K003 ESTIMATE OF THE INCIDENCE OF DRUG-FACILITATED SEXUAL ASSAULT IN THE U.S. FINAL REPORT Report prepared by: Adam Negrusz, Ph.D. Matthew Juhascik, Ph.D. R.E. Gaensslen, Ph.D. Draft report: March 23, 2005 Final report: June 2, 2005 Forensic Sciences Department of Biopharmaceutical Sciences (M/C 865) College of Pharmacy University of Illinois at Chicago 833 South Wood Street Chicago, IL 60612 ABSTRACT The term drug-facilitated sexual assault (DFSA) has been recently coined to describe victims who were given a drug by an assailant and subsequently sexually assaulted. Previous studies that have attempted to determine the prevalence of drugs in sexual assault complainants have had serious biases. This research was designed to better estimate the rate of DFSA and to examine the social aspects surrounding it. Four clinics were provided with sexual assault kits and asked to enroll sexual assault complainants.
    [Show full text]
  • Revista Electrónica De Psicología Iztacala
    Revista Electrónica de Psicología Iztacala. 18, (3), 2015 962 Revista Electrónica de Psicología Iztacala I Z T A C A L A Universidad Nacional Autónoma de México Vol. 18 No. 3 Septiembre de 2015 EL SINDROME DE LA FATIGA CRÓNICA (SFC) Y LAS BENZODIAZEPINAS Benita Cedillo-Ildefonso1, Constanza Miralrio Medina2, Norma Coffin Cabrera3 Universidad Nacional Autónoma de México Facultad de Estudios Superiores Iztacala RESUMEN El SFC es una enfermedad que afecta la calidad de vida de las personas y es difícil de hablar de una sola causa, ya que las investigaciones han detectado varios factores desencadenantes, como por ejemplo la ansiedad y la depresión. Uno de los síntomas que se presentan en los trastornos de ansiedad generalizada es fatigarse rápidamente, acompañándose de alteraciones del sueño y problemas de concentración (todos ellos síntomas típicos de la fatiga crónica). Estos síntomas del SFC se han tratado con fármacos como las benzodiazepinas, cuyo margen de seguridad es alto comparado con el de los barbitúricos. Las benzodiazepinas son ansiolíticos que se prescriben para el tratamiento de la ansiedad, alteraciones del sueño y otros síntomas. El objetivo del presente estudio teórico fue mostrar la relación de los síntomas como la ansiedad con la presencia del SFC y su tratamiento con las benzodiazepinas. Palabras clave: síndrome de fatiga crónica, benzodiazepinas, GABA, ansiedad y depresión 1 Profesor Asociado C TC definitivo, FES Iztacala, UNAM correo electrónico: [email protected] 2 Profesor Asociado B TC definitivo, FES Iztacala, UNAM correo electrónico: [email protected] 3 Profesor Titular A TC definitivo, FES Iztacala, UNAM correo electrónico: [email protected] www.revistas.unam.mx/index.php/repi www.iztacala.unam.mx/carreras/psicologia/psiclin Revista Electrónica de Psicología Iztacala.
    [Show full text]